CJC-1295 Research: The GHRH Receptor, the Albumin Linker, and the Pulsatile Signal

CJC-1295 binds a class-B G-protein-coupled receptor on pituitary somatotrophs, amplifies the body's own pulsatile growth hormone release, and — in its DAC variant — keeps the signal running for days. The molecular detail and the published results.

See the dosage record →Read the references →

I. · CJC-1295 Mechanism of Action

CJC-1295 Mechanism of Action

CJC-1295 binds the growth hormone-releasing hormone receptor — GHRHR, encoded on chromosome 7p14.3 — a class B G-protein-coupled receptor on pituitary somatotrophs [20]. Agonist binding activates the Gαs subunit, raises intracellular cAMP through adenylyl cyclase, activates protein kinase A, phosphorylates CREB, induces the somatotroph-specific transcription factor Pit-1, and triggers voltage-gated Ca2+ influx that drives exocytosis of preformed GH secretory granules [05]. The receptor's cryo-EM structure was published in 2020 [05]; a 2025 review of GHRHR signaling frames it as the single shared molecular target across every clinically studied GHRH analog — sermorelin, tesamorelin, CJC-1295, modified GRF 1-29 [20].

The pulse architecture matters. Endogenous GH is released in discrete bursts, chiefly during slow-wave sleep, not continuously. GHRH analogs amplify the amplitude of those bursts; exogenous recombinant GH overrides the rhythm with sustained apulsatile elevation. This is the mechanistic argument for studying GHRH analogs at all: they work with the body's clock rather than overriding it.

GHRH receptor agonism and pulsatile GH amplification

CJC-1295 binds pituitary GHRHR and amplifies endogenous pulsatile GH release from somatotrophs rather than supplying exogenous GH itself. The DAC variant extends this amplification across days; the non-DAC variant produces a single GH pulse lasting roughly 60-90 minutes versus 15-20 minutes for native sermorelin [13].

Plate VI: sumi-e GHRH receptor hexagon with a brushstroke ligand, an isometric scaffold to a somatotroph cell, and three rising pulsatile strokes, with a vermillion seal on rice paper — Plate VI · 図六 · GHRH receptor mechanismCJC-1295 binds pituitary GHRH receptors (GHRHR, class B GPCR) on somatotrophs, activates Gαs / cAMP / PKA / CREB / Pit-1 signaling, and amplifies pulsatile GH exocytosis.

II. · CJC-1295 DAC vs CJC-1295 (Modified GRF 1-29)

CJC-1295 DAC vs CJC-1295 (Modified GRF 1-29)

CJC-1295 DAC and the variant sold as CJC-1295 no DAC are two distinct peptides with the same 29-residue backbone. The difference is one linker.

The DAC linker is a maleimidopropionyl group attached to a 30th C-terminal lysine. In plasma, the maleimide reacts selectively with the free thiol of Cys34 on human serum albumin to form a stable covalent thioether [02][12]. The conjugated peptide rides circulating albumin, whose half-life is near 19 days, and is shielded from renal and proteolytic clearance. In Teichman's healthy-adult trials, plasma CJC-1295 was estimated at a 5.8- to 8.1-day half-life and produced pharmacologically relevant GH and IGF-1 elevation for six to eleven days from a single subcutaneous injection [01].

In ConjuChem's preclinical rat assay, albumin-bound CJC-1295 immunoreactivity appeared in circulation within 15 minutes of injection and persisted beyond 72 hours [03][14]. The same paper identified CJC-1295 as the most potent of three maleimido hGRF(1-29) bioconjugates synthesized, producing a four-fold increase in GH area-under-curve over two hours compared with unmodified hGRF(1-29) in cultured rat anterior pituitary cells [03].

CJC-1295 without DAC (Modified GRF 1-29)

CJC-1295 no DAC is the same peptide minus the albumin linker. Its half-life in plasma is approximately 30 minutes — extended from native sermorelin's sub-10-minute half-life by the DPP-IV-resistant substitutions, but no longer than that [04][13]. Research protocols administer it as multiple daily subcutaneous injections, typically 100-500 mcg per injection, one to three times daily [13]. The GH pulse it generates is roughly 60-90 minutes long, a more physiologic 'pulse-like' release pattern than the multi-day signal the DAC variant produces.

Modified GRF 1-29 (Tetra-Substituted GHRH 1-29)

Modified GRF 1-29 is the scientific name for tetrasubstituted GHRH(1-29) — the same peptide as CJC-1295 no DAC, with the same four substitutions (D-Ala2, Gln8, Ala15, Leu27) [02]. The 'modified GRF' nomenclature is the one used in mechanistic and pharmacokinetic literature; 'CJC-1295 no DAC' is the lay-and-research-chemical label. Treating the two terms as synonyms is correct; treating modified GRF 1-29 as equivalent to the DAC variant is not.

Plate II: sumi-e albumin sphere with an isometric linker scaffold extending to an implied peptide tail, with a vermillion seal in the lower-right on rice paper — Plate II · 図二 · DAC albumin-binding linkerThe DAC linker — a maleimidopropionyl group on a C-terminal lysine — covalently couples CJC-1295 to Cys34 of human serum albumin in vivo. The bound peptide rides albumin's ~19-day circulating half-life.

III. · Researched Effects of CJC-1295

Researched Effects of CJC-1295

Two pharmacodynamic endpoints anchor the literature. First, growth hormone: single ascending subcutaneous doses up to 250 mcg/kg in healthy adults produced two- to ten-fold elevations in mean plasma GH sustained for six days or more [01]. Second, IGF-1: those same doses raised mean serum IGF-1 1.5- to 3-fold for nine to eleven days [01]. Multiple-dose Phase 1 trials, with weekly or biweekly subcutaneous administration, maintained mean IGF-1 above baseline for up to 28 days [01].

In the cultured rat anterior pituitary assay, CJC-1295 produced a four-fold increase in GH area-under-curve over two hours compared to unmodified hGRF(1-29) [03]. Pulsatile release was preserved — the analog amplified existing pulse amplitude rather than collapsing the pulse architecture into continuous elevation [01].

No published Phase 2 efficacy data has appeared in peer-reviewed form. ConjuChem registered NCT00267527 for HIV-associated visceral obesity, enrolling roughly 192 adults on weekly escalating doses of 60-240 mcg/kg [18]. The program was halted before completion, and the efficacy endpoints — body composition, visceral fat reduction, IGF-1 area-under-curve — were never published.

Plate III: three asymmetric sumi brushstroke gestures representing pulsatile GH peaks above a quiet baseline rule, with a vermillion seal in the lower-right on rice paper — Plate III · 図三 · Pulsatile GH amplificationPulsatile GH bursts amplified by CJC-1295 — Teichman 2006 reported two- to ten-fold elevations sustained for six days or more after a single subcutaneous dose.

IV. · CJC-1295 Results in Published Trials

CJC-1295 Results in Published Trials

Two peer-reviewed primary papers carry most of the load. Jetté 2005 in Endocrinology is the preclinical pharmacology paper: receptor binding, in vitro pituitary cell secretion, in vivo rat plasma persistence, and identification of CJC-1295 as the most potent of three maleimido bioconjugates [03]. Teichman 2006 in JCEM is the human Phase 1 paper: two ascending-dose trials in healthy adults, the 5.8- to 8.1-day half-life, the two- to ten-fold GH elevation, the 1.5- to 3-fold IGF-1 elevation, the 28-day multi-dose IGF-1 trajectory [01].

Analytical literature has continued. Henninge 2010 confirmed CJC-1295's identity in a seized pharmaceutical preparation by LC-HRMS/MS, establishing reference data for anti-doping detection [08]. Timms 2019 developed an immunoaffinity-capture LC-MS/MS confirmation for albumin-bound CJC-1295 in equine plasma [09]. A 2021 review surveyed antibody-free nano-LC-HRMS/MS methods capable of detecting GHRH synthetic analogs at sub-picogram-per-milliliter sensitivity in urine [19]. The compound is a Prohibited Substance under Section S2 of the World Anti-Doping Agency Code and is detected by validated assays in WADA-accredited laboratories [15].

V. · Time course of reported effects in published stu

Time course of reported effects in published studies

Pulsatile GH amplitude rose within 24 to 48 hours of a single subcutaneous dose in healthy adults and remained elevated for six to nine days; serum IGF-1 rose more slowly and stayed elevated for nine to eleven [01]. In the 28- to 49-day multi-dose Phase 1 trials, weekly or biweekly subcutaneous administration of 30-60 mcg/kg maintained mean IGF-1 above baseline across the full trial window [01]. No published trial has reported a body-composition endpoint in the public literature.

VI. · CJC-1295 vs Ipamorelin: Class and Mechanism

CJC-1295 vs Ipamorelin: Class and Mechanism

CJC-1295 is a GHRH analog. Ipamorelin is a growth hormone secretagogue receptor agonist — it binds GHS-R1a, the ghrelin receptor, not the GHRH receptor [10]. The two molecules act on two different receptors that signal through two different intracellular cascades and converge on the same target cell. GHRHR signals through Gαs / cAMP / PKA; GHS-R1a signals through Gq / PLC / IP3 / Ca2+ [05][10]. Co-administration of a GHRH receptor agonist with a GHS-R agonist produced GH responses substantially greater than either alone in the Bowers laboratory's clinical pharmacodynamic studies, because the two pathways converge synergistically on somatotroph GH exocytosis rather than competing [10].

This is a mechanistic observation about receptor pharmacology in the published record. It is not an endorsement of any stacking protocol. The portfolio is editorial.

VII. · Endpoints in published trials

Endpoints in published trials

Across the Teichman 2006 record the measured endpoints were: pulsatile GH amplitude and area-under-curve, mean serum GH across the dosing interval, serum IGF-1, serum IGFBP-3, the pharmacokinetic parameters of the peptide itself (peak plasma concentration, time to peak, half-life), and adverse-event tracking [01]. The Phase 2 HIV lipodystrophy program (NCT00267527) added visceral adipose tissue by imaging as the primary efficacy endpoint, but that data was never published [18].

VIII. · Research applications studied to date

Research applications studied to date

CJC-1295 has been studied as a long-acting GH secretagogue in healthy adults (Teichman 2006 Phase 1) and in HIV-associated visceral obesity (the discontinued Phase 2 NCT00267527) [01][18]. Preclinical work has examined GHRH receptor binding, pituitary cell secretion, rat plasma pharmacokinetics, and the albumin-bioconjugation kinetics that underwrite the weekly-dosing model [03][14]. The compound has also been studied in animal models of muscle, bone, and fat metabolism as a tool for amplifying the GH/IGF-1 axis in research contexts. No published study has demonstrated meaningful change in serum testosterone — CJC-1295 acts on the GHRH/GH/IGF-1 axis, not the hypothalamic-pituitary-gonadal axis [01].